Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000824312 | SCV000965205 | pathogenic | Wilson disease | 2024-01-12 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 1341 of the ATP7B protein (p.Gly1341Asp). This variant is present in population databases (rs779494870, gnomAD 0.003%). This missense change has been observed in individuals with Wilson disease (PMID: 16283883, 21610751, 21682854, 22484412). ClinVar contains an entry for this variant (Variation ID: 665925). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Gly1341 amino acid residue in ATP7B. Other variant(s) that disrupt this residue have been observed in individuals with ATP7B-related conditions (PMID: 14639035, 16088907, 17264425, 19937698, 21682854), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000824312 | SCV001977216 | likely pathogenic | Wilson disease | 2021-08-10 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000824312 | SCV002800457 | likely pathogenic | Wilson disease | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000824312 | SCV004216345 | pathogenic | Wilson disease | 2024-03-19 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480876 | SCV004226640 | pathogenic | not provided | 2023-03-07 | criteria provided, single submitter | clinical testing | PP3, PP4, PM2, PM3_strong, PM5, PS4_moderate |
Natera, |
RCV000824312 | SCV001455574 | pathogenic | Wilson disease | 2020-09-16 | no assertion criteria provided | clinical testing |